A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
BACKGROUND AND AIMS: While glucagon-like peptide-1 receptor agonists (GLP-1RAs) effectively reduce body weight, their impact on lean mass remains uncertain. This meta-analysis evaluated the effects of GLP-1RAs and GLP-1/GIP receptor dual agonists (GL…
OBJECTIVE: To identify patients who may or may not benefit from use of new drugs for weight loss and to aid in minimizing loss of lean mass through proactive nutrition and exercise interventions. QUALITY OF EVIDENCE: Choices and interventions are eva…
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as an important therapeutic option for type 2 diabetes mellitus (T2DM), available in both oral and subcutaneous formulations. While subcutaneous semaglutide has been availab…
BACKGROUND: People with lower extremity peripheral artery disease (PAD) suffer from a high burden of symptoms and significant functional impairment. There are few therapies that improve function and reduce symptoms in this population. Glucagon-like p…
PURPOSE: Endoscopic sleeve gastroplasty (ESG) and GLP-1RA are proven obesity interventions with potential to aid patients who have MASLD. However, their comparative effectiveness remains unclear. This study aimed to compare ESG and semaglutide in MAS…
IMPORTANCE: Obesity, a chronic disease with escalating global prevalence, poses considerable health risks. Glucagon-like peptide 1 receptor agonists (GLP-1RAs), including liraglutide, semaglutide, and tirzepatide, have demonstrated efficacy for weigh…
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are at the forefront of treating the global health crisis of diabetes mellitus (DM) and obesity. However, the demand for GLP-1 RAs has far outstripped its supply and comes with a high monthly cost…
BACKGROUND: The cardioprotective effects of glucagon-like peptide-1 receptor agonist (GLP-1RA)-based therapies in nondiabetic individuals with overweight or obesity remain underexplored. This meta-analysis evaluates their impact on cardiovascular eve…
Semaglutide, a GLP-1 receptor agonist, has emerged as a promising agent in cardiovascular disease management, particularly for patients with obesity and diabetes. Recent studies have demonstrated significant benefits of Semaglutide beyond glycemic co…
Autoimmune thyroid disease (AITD), including Hashimoto thyroiditis and Graves' disease, represents the most prevalent organ-specific autoimmunity and a major cause of thyroid dysfunction worldwide. Increasingly, AITD coexists with metabolic disorders…
PURPOSE: This study aims to investigate the possible impacts of fasting on physical activity and weight loss in adult users of glucagon-like peptide-1 (GLP-1) agonists, specifically semaglutide and tirzepatide, using qualitative methods to gain in-de…
AIMS: To evaluate the risk of incident suicidal ideation (SI) and suicidality (SI, suicide attempt or intentional self-harm) among overweight or obese adults who were prescribed semaglutide for weight management compared with active comparators (weig…
OBJECTIVE: This study aimed to identify clinical predictors associated with reductions in HbA1c and weight among patients with type 2 diabetes mellitus (T2DM) treated with semaglutide in real-world clinical settings in Bulgaria. METHODS: A retrospect…
INTRODUCTION: Weight gain has come to define the life experience of many individuals with schizophrenia and other severe enduring mental illnesses (SMI). In this clinical intervention study, we aimed to determine whether weekly treatment with the glu…
BACKGROUND: No head-to-head comparisons of semaglutide formulations currently exist in the literature. In practice, many may think that oral and injectable semaglutide formulations are interchangeable, although there is currently limited real-world d…
The increasing prevalence of type 2 diabetes presents a major global health challenge. Glucagon-like peptide-1 (GLP-1) receptor agonists offer glycemic control, weight loss, and cardiovascular benefits but are limited by rapid enzymatic degradation a…
Obesity is heterogeneous and considered a chronic epidemic with significant un-met needs for management, treatment, and prevention.In this study, we used LizAI's software TAITAN (alpha version) for the mega-collection and analysis of clinical data fr…